Rapid Bio raises $7.2M to expand diagnostics portfolio
What's the deal? Russian diagnostics developer Rapid BioDealroom has a profile for this one. Try Dealroom → has raised US$9.02M in a growth equity round led by venture firm Kama FlowDealroom has a profile for this one. Try Dealroom →. The size of the stake taken by the investor was not disclosed.
What's the endgame? Rapid Bio will use the funds to expand its portfolio of test systems for continuous glucose monitoring and early diagnosis of neurodegenerative diseases, including Alzheimer's and strokes. It also plans new tests based on next-generation sequencing (NGS) for preimplantation genetic testing and oncology.
Founded in 2020 in Ulan-Ude, Rapid Bio is a resident of the Skolkovo innovation hub. It runs five R&D labs in Moscow and St Petersburg, holds more than 30 finished products with around 90 in development, and has capacity to make up to 180 million tests a year.
By the numbers: Rapid Bio's revenue rose 13% in 2025, to US$9.2M, but the company posted a net loss of US$1.7M against a profit a year earlier. It estimates the market potential in its target segments by 2027–2028 at US$285.5M for diabetes, US$93.2M for Alzheimer's, and US$60.1M for NGS-based products.
About the investor: Kama Flow, founded in 2013 in Moscow, manages funds with assets valued at more than US$225.4M and holds stakes in over 30 companies. Its main entity, KF VenturesDealroom has a profile for this one. Try Dealroom →, saw revenue rise 10% in 2025, to US$375.7K, while posting a net loss of US$601.1K.
What could go wrong? Most of Rapid Bio's test systems sell through business-to-business channels and government procurement, where analysts do not track full statistics. Retail demand is uneven: in January to July, pharmacy sales of COVID-19 tests fell 32% year on year, though HIV tests rose 30%.
The signal: At roughly $7.2 million, the round ranks in the lower tier of disclosed venture deals by size, but it targets a fragmented and growing diagnostics market. Only a small share of rapid tests are designed for patient self-use, and their results still require lab confirmation — leaving room for developers building broader clinical portfolios.
Read more: kommersant.ru
Image credit: Generated with Gemini
